• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Rtw Investments, Lp

    4/22/26 4:15:07 PM ET
    $KLRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KLRA alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
    X
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    RTW INVESTMENTS, LP

    (Last)(First)(Middle)
    40 10TH AVENUE, FLOOR 7

    (Street)
    NEW YORK NEW YORK 10014

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    Kailera Therapeutics, Inc. [ KLRA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    04/20/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    XForm filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Common Stock04/20/2026C10,276,820A(1)10,276,820ISee footnote(2)
    Common Stock04/20/2026P500,000A$1610,776,820ISee footnote(2)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Series A Preferred Stock(1)04/20/2026C8,250,000 (1) (1)Common Stock8,250,000(1)0ISee footnote(2)
    Series B Preferred Stock(1)04/20/2026C2,026,820 (1) (1)Common Stock2,026,820(1)0ISee footnote(2)
    1. Name and Address of Reporting Person*
    RTW INVESTMENTS, LP

    (Last)(First)(Middle)
    40 10TH AVENUE, FLOOR 7

    (Street)
    NEW YORK NEW YORK 10014

    (City)(State)(Zip)

    UNITED STATES

    (Country)

    Relationship of Reporting Person(s) to Issuer
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    1. Name and Address of Reporting Person*
    WONG RODERICK

    (Last)(First)(Middle)
    C/O RTW INVESTMENTS, LP
    40 10TH AVENUE, FLOOR 7

    (Street)
    NEW YORK NEW YORK 10014

    (City)(State)(Zip)

    UNITED STATES

    (Country)

    Relationship of Reporting Person(s) to Issuer
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    Explanation of Responses:
    1. Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-1 basis and had no expiration date.
    2. Held by certain affiliated funds managed by RTW Investments, LP ("RTW"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of RTW. The Reporting Persons disclaim beneficial ownership of the reported securities for purposes of Section 16 under the Securities Exchange Act of 1934, as amended, except to the extent of their pecuniary interest therein.
    /s/ Roderick Wong, for RTW Investments, LP, By: Roderick Wong, M.D., Managing Partner04/22/2026
    /s/ Roderick Wong, By: Roderick Wong, M.D.04/22/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $KLRA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KLRA

    DatePrice TargetRatingAnalyst
    5/12/2026$30.00Overweight
    Analyst
    5/12/2026Outperform
    William Blair
    5/12/2026$36.00Outperform
    Leerink Partners
    5/12/2026$57.00Buy
    TD Cowen
    5/12/2026Outperform
    Evercore ISI
    5/12/2026$48.00Buy
    Jefferies
    More analyst ratings

    $KLRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Officer Tregoning Kathleen

    4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)

    7/8/26 4:20:04 PM ET
    $KLRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Tregoning Kathleen

    3 - Kailera Therapeutics, Inc. (0002096997) (Issuer)

    7/8/26 4:15:04 PM ET
    $KLRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO & President Renaud Ronald C Jr exercised 38,094 shares at a strike of $5.25 (SEC Form 4)

    4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)

    6/11/26 4:05:10 PM ET
    $KLRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KLRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst initiated coverage on Kailera Therapeutics with a new price target

    Analyst initiated coverage of Kailera Therapeutics with a rating of Overweight and set a new price target of $30.00

    5/12/26 8:32:38 AM ET
    $KLRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Kailera Therapeutics

    William Blair initiated coverage of Kailera Therapeutics with a rating of Outperform

    5/12/26 8:32:38 AM ET
    $KLRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Kailera Therapeutics with a new price target

    Leerink Partners initiated coverage of Kailera Therapeutics with a rating of Outperform and set a new price target of $36.00

    5/12/26 8:32:17 AM ET
    $KLRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KLRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535

    In Phase 3 trial in obesity/overweight in China, HRS-7535 achieved a mean weight loss of up to 10.9% at Week 44 and a mean weight loss of up to 11.1% at Week 50 Kailera currently conducting global Phase 2 trial of KAI-7535 in obesity to further optimize KAI-7535's clinical profile for the treatment of obesityIn second Phase 3 trial in type 2 diabetes in China, HRS-7535 lowered HbA1c by an average of 1.50% to 1.68% across dosesLiver safety findings in both Phase 3 trials consistent with data generated to date; no liver safety signals observed WALTHAM, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Kailera), a clinical-stage biotechnology company focused on elevating t

    7/7/26 7:00:00 AM ET
    $KLRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer

    WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Kathleen Tregoning as Chief Corporate Affairs Officer. "We are delighted to welcome Kathleen to our leadership team as we advance our late-stage clinical trials in obesity and navigate the rapidly evolving obesity treatment landscape," said Ron Renaud, President and Chief Executive Officer of Kailera. "Kathleen is a seasoned executive with deep experience helping biopharmaceutical companies build trust, navigate complexity, and engage stakeholders around a shared mission. Her strategic per

    6/29/26 7:30:00 AM ET
    $KLRA
    $CMPS
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

    Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and overweightAdditional data from Phase 2 obesity clinical trial of ribupatide oral demonstrating mean weight loss of up to 12.1% with no observed plateau and up to 38.6% of participants achieving at least 15% weight loss at 26 weeks; incidence of gastrointestinal adverse events was low, with vomiting reported in 11.4% and 7.5% of participants taking 25 mg and 50 mg ribupatide oral, respectivelyPhase 1 single ascending dose trial, the first ribupatide injection clinical data generated outside of China

    6/5/26 7:32:00 PM ET
    $KLRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KLRA
    SEC Filings

    View All

    SEC Form 10-Q filed by Kailera Therapeutics Inc.

    10-Q - Kailera Therapeutics, Inc. (0002096997) (Filer)

    5/26/26 4:29:25 PM ET
    $KLRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kailera Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Kailera Therapeutics, Inc. (0002096997) (Filer)

    5/26/26 4:18:46 PM ET
    $KLRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13D filed by Kailera Therapeutics Inc.

    SCHEDULE 13D - Kailera Therapeutics, Inc. (0002096997) (Subject)

    4/23/26 8:01:50 PM ET
    $KLRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KLRA
    Leadership Updates

    Live Leadership Updates

    View All

    Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer

    WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Kathleen Tregoning as Chief Corporate Affairs Officer. "We are delighted to welcome Kathleen to our leadership team as we advance our late-stage clinical trials in obesity and navigate the rapidly evolving obesity treatment landscape," said Ron Renaud, President and Chief Executive Officer of Kailera. "Kathleen is a seasoned executive with deep experience helping biopharmaceutical companies build trust, navigate complexity, and engage stakeholders around a shared mission. Her strategic per

    6/29/26 7:30:00 AM ET
    $KLRA
    $CMPS
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care